A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis
Open Access
- 1 November 2003
- journal article
- Published by Elsevier in Molecular Therapy
- Vol. 8 (5) , 707-717
- https://doi.org/10.1016/s1525-0016(03)00235-1
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Rheumatoid arthritisPublished by Elsevier ,2001
- Adenoviral Transfer of Cyclin-Dependent Kinase Inhibitor Genes Suppresses Collagen-Induced Arthritis in MiceThe Journal of Immunology, 2000
- Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed CellsJNCI Journal of the National Cancer Institute, 2000
- Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritisNature Medicine, 1999
- Anticytokine Therapy in Rheumatoid ArthritisNew England Journal of Medicine, 1997
- Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion ProteinNew England Journal of Medicine, 1997
- The role of T cells in the immunopathogenesis of rheumatoid arthritis. New perspectivesArthritis & Rheumatism, 1997
- Anti-Tumor Necrosis Factor-α Therapy of Rheumatoid ArthritisPublished by Elsevier ,1997
- Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid DiseaseImmunological Reviews, 1995
- Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritisArthritis & Rheumatism, 1995